Feasibility study of pemetrexed / bevacizumab / erlotinib in chemotherapy naïve patients with non- small cell lung cancer harboring EGFR mutatio
- Conditions
- on-Small Cell Lung Cancer, Non-Squamous cell lung cancer
- Registration Number
- JPRN-UMIN000014477
- Lead Sponsor
- ational Hospital Organization Kyushu Medical Center,Department of Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Not provided
1)Interstitial pneumonia/lung fibrosis on chest X-ray 2)History of chest radiation therapy 3)History or complication of hemoptysis with 2.5ml per time or more and Continuous bloody phlegm more than 1 week or complication of bloody phlegm treated with continuous oral hemostatic agent. History or complication of bloody phlegm treated with infusional hemostatic agent. 4)Evidence of tumor invading a perihilar blood vessel, heart and major blood vessel on imaging 5)Evidence of tumor invading segmental bronchus 6)Symptomatic brain metastasis 7)Active hepatic disease 8)Having serious complications 9)Uncontrolled ascites, pleural effusion or cardiac effusion 10) History of multiple malignancies within 3 years 11) Planning of surgery during the trial 12) A pregnant woman, a nursing girl and woman with the possibility (intention) of the pregnancy, and 13) Having serious mental disorder 14) Previous drug allergy 15) Those judged to be not suitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility of Pemetrexed/Bevacizumab/Erlotinib
- Secondary Outcome Measures
Name Time Method Anti-tumor efficacy